Introduction

In the current study, we evaluated factors that increase the coronavirus disease (COVID-19) patient death rate by analyzing the data from two cohort hospitals. In addition, we studied whether underlying neurological diseases are risk factors for death.

Methods

In this retrospective cohort study, we included 103 adult inpatients (aged ≥ 18 years). We evaluated differences in demographic data between surviving and non-surviving COVID-19 patients.

Results

In a multivariate logistic analysis, age and the presence of chronic lung disease and Alzheimer’s dementia (AD) were the only significant parameters for predicting COVID-19 non-survival (p < 0.05). However, hypertension, coronary vascular disease, dyslipidemia, chronic kidney disease, diabetes, and history of taking angiotensin II receptor blockers (ARBs) or angiotensin-converting enzyme (ACE) inhibitors, as well as nonsteroidal anti-inflammatory drugs (NSAIDs), were not significantly associated with the death of COVID-19 patients. The optimal cutoff value obtained from the maximum Youden index was 70 (sensitivity, 80.77%; specificity, 61.04%), and the odds ratio of non-survival increased 1.055 fold for every year of age.

Conclusions

Clinicians should closely monitor and manage the symptoms of COVID-19 patients who are over the age of 70 years or have chronic lung disease or AD.

中文翻译：

---

神经系统疾病作为 COVID-19 患者的预测因素：一项回顾性队列研究。

介绍

在当前的研究中，我们通过分析来自两家队列医院的数据，评估了增加冠状病毒病 (COVID-19) 患者死亡率的因素。此外，我们研究了潜在的神经系统疾病是否是死亡的危险因素。

方法

在这项回顾性队列研究中，我们纳入了 103 名成年住院患者（年龄≥18 岁）。我们评估了幸存和未幸存的 COVID-19 患者之间人口统计数据的差异。

结果

在多变量逻辑分析中，年龄和是否存在慢性肺病和阿尔茨海默病痴呆 (AD) 是预测 COVID-19 无法存活的唯一重要参数 ( p  <0.05)。然而，高血压、冠状动脉血管疾病、血脂异常、慢性肾脏疾病、糖尿病和服用血管紧张素 II 受体阻滞剂 (ARBs) 或血管紧张素转换酶 (ACE) 抑制剂以及非甾体类抗炎药 (NSAIDs) 的病史，与 COVID-19 患者的死亡没有显着相关性。从最大约登指数获得的最佳截止值为70（敏感性为80.77%；特异性为61.04%），非存活的优势比随着年龄的增长而增加1.055倍。

结论

临床医生应密切监测和管理 70 岁以上或患有慢性肺病或 AD 的 COVID-19 患者的症状。